They administered lapatinib as a single agent in vivo for four types of pancreatic cancer cell lines (MiaPaca-2, PANC-1, Capan-1, and Capan-2) to identify HER2/EGFR expressions in each of the four pancreatic cancer cells. This evidence concerns the gene ERBB2 and pancreatic neoplasm.